[{"id":"b597d602-e328-4393-8c98-df171f694e55","acronym":"HLX11-BC301","url":"https://clinicaltrials.gov/study/NCT05346224","created_at":"2022-04-26T15:01:51.159Z","updated_at":"2025-02-25T13:54:23.669Z","phase":"Phase 3","brief_title":"A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer","source_id_and_acronym":"NCT05346224 - HLX11-BC301","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • ER negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide • Poherdy (pertuzumab-dpzb)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 900","initiation":"Initiation: 04/25/2022","start_date":" 04/25/2022","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-04-16"}]